Treatment of Adult Patients With Immune Thrombocytopenia After Failure of First-Line Therapies


Project Status:
Project Line:
Health Technology Review
Project Sub Line:
Health Technology Assessment
Project Number:
Effective finish date:

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelets and an increase in bleeding risk. 

This Health Technology Assessment is a narrative review of 15 publications (including 10 randomized controlled trials) found through a systematic literature search. The review addressed the following policy questions: what treatment(s) should be used in adult patients with ITP who have failed first-line treatments, and what is the place in therapy of splenectomy in adult patients with ITP? 

This review found that eltrombopag and romiplostim increased platelet count response and improved ITP symptoms and health-related quality of life when compared to placebo. There was a lack of evidence in specific subgroups of patients and on the role of splenectomy in the sequency of subsequent-line therapies.